昆藥集團(600422.SH)擬3000萬元戰略投資漢光藥業 佔股6.98%
格隆匯 12 月 29日丨昆藥集團(600422.SH)公佈,鑑於公司與漢光藥業在產品管線和銷售渠道上具有強互補性,通過此次戰略合作,有助於公司持續豐富在骨科、心腦血管等治療領域的產品管線,並進一步打通零售渠道,加速實現“處方-零售”雙輪驅動戰略落地,公司擬以增資形式對漢光藥業進行戰略投資,投資金額為人民幣3000萬元,增資完成後公司持有漢光藥業307.95萬股股份,佔漢光藥業股份總數的6.98%。
漢光藥業擁有獨家進口代理權和MAH持證的專科領先產品與公司打造“小而美”專科產品管線戰略高度契合,同時漢光藥業全國獨家代理的零售通路系列產品與公司重點打造的零售渠道高度協同。
鑑於雙方在產品管線和銷售渠道上的強互補性,此次公司戰略投資漢光藥業,第一,將有助於公司持續豐富骨科、心腦血管、精神神經類等專科領域的產品管線,強化公司在該等領域的市場競爭力;第二,藉助與漢光藥業在零售產品線的深度合作,公司將進一步打通零售渠道,加速實現公司“處方-零售”雙輪驅動戰略落地;第三,針對漢光藥業獲批上市的產品,在同等核心商務條款下,公司將優先獲得合作推廣權利,同時,雙方將在新產品研發和外部產品引進方面開展合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.